Cargando…

Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

BACKGROUND: This observational study explored the prevalence of metabolic syndrome (MetS) in adult in- and outpatients with untreated or treated schizophrenia at baseline, and month-3 after initiation or switch of antipsychotic treatment. METHODS: MetS-prevalence (AHA/NHLB-definition) was assessed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kraemer, Susanne, Minarzyk, Anette, Forst, Thomas, Kopf, Daniel, Hundemer, Hans-Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305894/ https://www.ncbi.nlm.nih.gov/pubmed/22044502 http://dx.doi.org/10.1186/1471-244X-11-173

Ejemplares similares

Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study
por: Kraemer, Susanne, et al.
Publicado: (2013)

Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
por: Jaberi, Nayyer, et al.
Publicado: (2020)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia
por: Freyberg, Zachary, et al.
Publicado: (2017)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics
por: McEvoy, Joseph, et al.
Publicado: (2013)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu, Xiaoli, et al.
Publicado: (2014)

Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview
por: Borovcanin, Milica M, et al.
Publicado: (2021)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients
por: Chadda, Rakesh K., et al.
Publicado: (2013)

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
por: Ijaz, Sharea, et al.
Publicado: (2018)

The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics
por: Ko, You-Kyung, et al.
Publicado: (2013)

Prevalence of obesity in primary care using different anthropometric measures – Results of the German Metabolic and Cardiovascular Risk Project (GEMCAS)
por: Hauner, Hans, et al.
Publicado: (2008)

Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
por: Kang, Shi Hyun, et al.
Publicado: (2015)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

antipsychotics and metabolic syndrome
por: Jomli, R., et al.
Publicado: (2022)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
por: Scigliano, Giulio, et al.
Publicado: (2013)

Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics
por: Chen, Po-Yu, et al.
Publicado: (2018)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
por: Mahlich, Jörg, et al.
Publicado: (2020)

Fatty Acid Desaturase Gene Polymorphisms and Metabolic Measures in Schizophrenia and Bipolar Patients Taking Antipsychotics
por: Burghardt, Kyle J., et al.
Publicado: (2013)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang, Xinyu, et al.
Publicado: (2019)

Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics
por: Naderyan Fe'li, Shadi, et al.
Publicado: (2019)

Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives
por: Chang, Shen-Chieh, et al.
Publicado: (2021)

Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms
por: Stelmach, Adriana, et al.
Publicado: (2022)

Audit on Baseline Physical and Metabolic Investigations Before Prescribing Antipsychotics in Children and Adolescent With Psychosis and Schizophrenia
por: Javaid, Sadia Tabassum, et al.
Publicado: (2023)

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients
por: Misiak, Błażej, et al.
Publicado: (2014)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes
por: Linck, Viviane M., et al.
Publicado: (2011)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Assessing Effects of Diet Alteration on Carbohydrate–Lipid Metabolism of Antipsychotic-Treated Schizophrenia Patients in Interventional Study
por: Friedrich, Mariola, et al.
Publicado: (2023)

Prevalence of infection in German ICUs: results from the German Prevalence Study
por: Brunkhorst, F, et al.
Publicado: (2006)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare:The German Metabolic and Cardiovascular Risk Project (GEMCAS)
por: Moebus, Susanne, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_14s84ap2fs8oi8m6j685f3o963